bimatoprost / Generic mfg. - LARVOL DELTA

Prostaglandin Analogues Attenuate Hyaluronan Accumulation in Orbital Fibroblast Cultures (ETA 2026) - "Cells were cultured in the presence or absence of PGAs: latanoprost, tafluprost or bimatoprost, or prostaglandin F2 (PF2), with or without PDGF-BB (10 ng/ml) stimulation of HA synthesis. PGAs modulate HA levels in orbital fibroblasts not only by suppressing synthesis but also by promoting degradation. This dual action may offer therapeutic benefits in TED, where the progression of the disease is driven by pathological HA accumulation."

Glaucoma • Ophthalmology • Thyroid Eye Disease • CEMIP • HAS 3 • HAS1 • HAS2 • HYAL1

Bimatoprost-Associated Lentigo Darkening During Scar Repigmentation. (PubMed, Dermatol Surg) - No abstract available

Journal

Comparative study between efficacy of Excimer light with topical Tacrolimus 0.1% versus excimer light with topical Bimatoprost 0.01% in treatment of facial Vitiligo (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Vitiligo

Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial (EADV 2026) - No abstract available

Clinical

Comparative study on the therapeutic efficacy of topical bimatoprost (0.03%) ophthalmic solution and tacrolimus (0.1%) ointment in stable vitiligo. (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Ophthalmology • Vitiligo

Local Pharmacokinetics and Tolerability of Topically-Applied Bimatoprost to the Scalp of Male Patients With Androgenetic Alopecia. (PubMed, Clin Transl Sci) - "In conclusion, there were no significant differences in bimatoprost concentration between Formulations A and B in the epidermis/dermis layer of the scalp samples from the same study participants, with levels above efficacious concentrations. Treatment with bimatoprost 1% Formulations A and B was well tolerated."

Journal • PK/PD data • Alopecia • Immunology

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: University of Maryland, Baltimore | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Mar 2026 ➔ Mar 2027

Biomarker • Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023. (PubMed, Cureus) - "We further narrowed our focus to studies that could be aggregated into the intervention categories: phototherapy and systemic combination therapy (n=10), topical and topical combination therapy (n=15), and systemic monotherapy (n=5).  Treated versus control subjects showed statistically improved VASI after the following interventions were added to phototherapy: oral psoralen, oral minipulsed prednisone, implanted afamelanotide, topical ethyl vanillate, topical bimatoprost, and oral vitamins A and E. Effective topical therapies were ruxolitinib, calcipotriol and betamethasone, tacrolimus and mometasone, and microdermabrasion and tacrolimus. None of the systemic monotherapies was superior to their corresponding comparator."

Journal • Review • Aesthetic Medicine • Dermatology • Immunology • Vitiligo

Multimodal imaging application of Sturge-Weber syndrome complicated with glaucoma: a case report of non-surgical treatment in a 7-year-old boy. (PubMed, BMC Ophthalmol) - "In selected pediatric SWS patients with refractory glaucoma, bimatoprost may achieve excellent IOP control, avoiding surgical risks. Multimodal imaging is essential for accurate diagnosis and monitoring. This case challenges the traditional view that topical medications are ineffective in SWS-related glaucoma and highlights the potential of prostaglandin analogs as a first-line or early adjunctive therapy."

Journal • Glaucoma • Ophthalmology • Pediatrics • Retinal Disorders

Glaucoma prevalence and prescribing trends in New Zealand: A 10-year study. (PubMed, Asia Pac J Ophthalmol (Phila)) - "This nationwide study provides the most comprehensive analysis to date of glaucoma medication dispensing in Aotearoa New Zealand, capturing real-world treatment patterns across a ten-year period. It offers critical insight into the treated prevalence and incidence of pharmacologically treated glaucoma and ocular hypertension at a population level. Latanoprost has clearly emerged as the dominant first-line therapy, consistent with international clinical guidelines, followed by Timolol. However, the findings also expose significant inequities: Māori-the Indigenous people of New Zealand-and Pasifika populations remain markedly under-represented among those receiving glaucoma treatment, even after adjusting for age. Further research is needed to understand the underlying reasons for these disparities and to ensure equitable access to glaucoma care for all New Zealanders."

Journal • Cardiovascular • Glaucoma • Ophthalmology

A Comparative, Randomized, Investigator-blind, Active-controlled, Parallel-group, Multicenter, Clinical Endpoint Study (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: YS Life Science Co., Ltd.

New P3 trial • Cardiovascular • Glaucoma • Ophthalmology

Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: SpyGlass Pharma, Inc.

New P1 trial • Cardiovascular • Glaucoma • Ophthalmology

A Comprehensive Review of the Clinical Evidence Comparing Benzalkonium Chloride-Preserved and Benzalkonium Chloride-Free Latanoprost in the Treatment of Primary Open-Angle Glaucoma and Ocular Hypertension. (PubMed, Clin Ophthalmol) - "Inclusion criteria were peer-reviewed clinical trials and meta-analyses comparing latanoprost with placebo or other treatments (eg. bimatoprost, travoprost, tafluprost, latanoprostene bunod)...Comparative studies indicate that latanoprost achieves a good balance between IOP reduction and tolerability compared to bimatoprost, travoprost, tafluprost, and unoprostone...Latanoprost remains a first-line therapy for POAG and OHT due to its efficacy, safety, and patient adherence. The availability of BAK-free formulations enhances its therapeutic profile, with reduced corneal toxicity making it a preferred choice for long-term glaucoma management."

Clinical • Journal • Review • Cardiovascular • Dermatology • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

Prostaglandin analogues in cosmetic products formulated for eyelash lengthening. (PubMed, Ann Pharm Fr) - "Six prostaglandin analogues were found, including bimatoprost and norbimatoprost. The most common are ethyl tafluprostamide, also known as dechloro dihydroxy difluoro ethyl cloprostenolamine (DDDE), and isopropyl cloprostenate...Conclusion : Serums containing prostaglandin analogues are therefore available on the market and are promoted as eyelash growth treatments. They pose a number of problems as they are not regulated for use in cosmetic products."

Journal

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - P1/2 | N=100 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Glaucoma • Ophthalmology

The prostaglandin F2α analog bimatoprost activates secondary hair germ cells to promote hair growth through two distinct signaling pathways (SID 2026) - "Together, our findings reveal that PGF2α analogs like bimatoprost promote hair progenitor cell population and hair growth through two independent pathways: a PTGFR-MAPK signaling axis and an IGF1R-PCAD-AKT signaling axis. In particular, the previously unrecognized IGF1R-PCAD-AKT signaling axis in the hair follicle establishes a mechanistic foundation for the potential targeting of hair follicle progenitor cells in the treatment of alopecic hair disorders."

CDH3 • IGF1

The prostaglandin F2α analog bimatoprost activates secondary hair germ cells to promote hair growth through two distinct signaling pathways (SID 2026) - "Together, our findings reveal that PGF2α analogs like bimatoprost promote hair progenitor cell population and hair growth through two independent pathways: a PTGFR-MAPK signaling axis and an IGF1R-PCAD-AKT signaling axis. In particular, the previously unrecognized IGF1R-PCAD-AKT signaling axis in the hair follicle establishes a mechanistic foundation for the potential targeting of hair follicle progenitor cells in the treatment of alopecic hair disorders."

CDH3 • IGF1

Frontal fibrosing alopecia with clinical improvement following dupilumab therapy: A case report (SID 2026) - "She was initially treated with doxycycline, dutasteride, oral minoxidil, and topical bimatoprost with minimal success. By six months, however, visible hair regrowth was observed. This case highlights a patient with frontal fibrosing alopecia unresponsive to standard therapies who demonstrated improvement in both dermatitis and FFA with use of dupilumab."

Case report • Clinical • Alopecia • Dermatitis • Fibrosis • Immunology

Efficacy and safety of netarsudil compared with prostaglandin-based therapies: a Bayesian network meta-analysis. (PubMed, Int Ophthalmol) - "The study aimed to compare the efficacy and safety of netarsudil (NET), alone or in fixed-dose combinations (FDC), in comparison with prostaglandin analogues (PGAs: bimatoprost [BIM], latanoprost [LAT], travoprost [TRA], and tafluprost [TAF]) for the treatment of primary open-angle glaucoma (POAG) or ocular hypertension. Although NET ranked lower in IOP-lowering efficacy compared to most PGAs and FDC, it demonstrated a favorable safety profile, particularly with a relatively lower incidence of conjunctival hyperemia than TAF and FDC. These findings suggest that NET may serve as a valuable alternative in patients who are intolerant to PGAs or require adjunctive therapy, warranting further investigation in targeted populations."

Clinical • Journal • Retrospective data • Cardiovascular • Glaucoma • Ophthalmology

Shifting Medicare Glaucoma Pharmacotherapy: Rising Costs and Increasing Use of New Mechanism Agents, 2019-2023 (ARVO 2026) - "Results From 2019-2023, utilization of several legacy agents declined sharply (e.g., Travatan Z from 291,097 to 7,534 claims; Combigan from 282,811 to 144,502 claims), while medications with new mechanism of action demonstrated steady growth, including Rhopressa (60,538 to 89,044 claims), Rocklatan (13,994 to 67,255 claims), and Vyzulta (21,280 to 69,308 claims)...Spending (market) shares showed parallel shifts: Lumigan decreased from 54% to 43% and Combigan from 33% to 14%, while medications with new mechanisms of action captured a growing share of total Medicare glaucoma spending – Rhopressa increasing from 7.1% to 10.7%, Rocklatan from 1.1% to 9.0%, and Vyzulta from 2.2% to 7.2%...Total spending rose nearly 50% despite declining overall utilization, underscoring the growing cost burden associated with newer, higher-cost branded agents. These findings highlight the need for cost-conscious prescribing strategies and further evaluation of affordability and access in..."

Medicare • Reimbursement • US reimbursement • Glaucoma • Ophthalmology

Incidence and Timing of Postoperative Intraocular Pressure Spikes Following Cataract Surgery: A Large Multi-Center United States Study (ARVO 2026) - "We defined IOP spikes as any new postoperative glaucoma diagnosis, postprocedural ocular hypertension, glaucoma procedure (laser trabeculoplasty, iridotomy, cyclophotocoagulation, canal/angle surgery, paracentesis, or tube shunt), or initiation of IOP-lowering medications (timolol, brimonidine, dorzolamide, brinzolamide, latanoprost, bimatoprost, netarsudil, pilocarpine, acetazolamide, or methazolamide). A secondary increase in IOP-related events was observed between 15 and 90 days, consistent with steroid-response physiology. Our findings highlight important temporal patterns in postoperative IOP behavior and underscore the need for targeted surveillance and risk stratification."

Clinical • Surgery • Cataract • Glaucoma • Ophthalmology

Post-Marketing Surveillance Reveals Amplified Adverse Event Burden Across Topical Pharmacotherapies for Primary Open-Angle Glaucoma (ARVO 2026) - "The FDA-approved drugs evaluated included bimatoprost, tafluprost, travoprost, latanoprost, omidenepag, timolol, brimonidine, brinzolamide, dorzolamide, netarsudil, brinzolamide-brimonidine, and brimonidine-timolol. With average trial lengths of 15 months versus chronic real-world use, post-marketing data reveal multisystem and mortality-associated safety signals not detected pre-approval. These findings highlight gaps in the POAG trial safety reporting and may support the need for extended pharmacovigilance beyond formal trial periods."

Adverse events • P4 data • Glaucoma • Ophthalmology

Prostaglandin Analogs and Glaucoma Eye Drop Prescription Patterns in Medicare Part D from 2014 to 2023 (ARVO 2026) - "Within the prostaglandin analog class, latanoprost was the most prescribed drug, whereas Lumigan incurred the highest annual cost...Additionally, Travatan Z maintained the second-highest total cost until a marked decline beginning in 2020, coinciding with the introduction of its generic version, Travoprost...The two most influential drugs affecting total cost were brand-name prostaglandins, one with a recently introduced generic and one without. This divergence in claims and cost trends highlights how prescription volume is primarily driven by disease prevalence, whereas drug cost is more strongly influenced by pharmaceutical cost."

Medicare • Reimbursement • US reimbursement • Glaucoma • Ophthalmology

High Resolution Laser speckle contrast imaging for quantifying episcleral vascular flow: effect of topical bimatoprost. (ARVO 2026) - "Further experiments are warranted to confirm and better characterize these effects. Moreover, the results highlight the utility of LSCI for detecting and quantifying changes in ocular blood flow following therapeutic interventions."

Ophthalmology

In Vivo Pharmacokinetic Evaluation of a Seven Days Sustained-Release Bimatoprost Ophthalmic Topical Insert Versus Bimatoprost Eye Drops in Rabbits (ARVO 2026) - "Conclusions A single administration of the sustained-release bimatoprost insert provided equivalent seven-day ocular exposure to daily drops despite a 50% lower total dose. This insert offers a patient-friendly, adherence-independent alternative for intraocular pressure management, with consistent exposure and reduced dosing burden."

PK/PD data • Preclinical • Glaucoma • Ocular Inflammation • Ophthalmology